CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction Clinical epidemiology of heart failure with preserved ejection fraction (HFpEF) in comparatively young hospitalized patients A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators - The RAID Trial Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure Cardiac Implantable Electronic Devices in Patients With Left Ventricular Assist Systems Lateral Wall Dysfunction Signals Onset of Progressive Heart Failure in Left Bundle Branch Block Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Review ArticleVolume 74, Issue 6, 13 August 2019, Pages 804-813

JOURNAL:J Am Coll Cardiol. Article Link

Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week

F Triposkiadis, A Xanthopoulos, J Butler et al. Keywords: aging; amyloidosis; comorbidities; heart failure; risk factors

ABSTRACT


Heart failure (HF) is a clinical syndrome that usually develops in the elderly. Complex interactions of the cardiovascular aging process with risk factors (obesity, hypertension, and atherosclerosis), comorbidities (anemia, chronic kidney disease, diabetes, and so on), and disease modifiers (sex, genes, others) contribute to the development of HF phenotype and outcome. A conglomerate of cellular and molecular mechanisms underlies the effects of aging on cardiovascular function, the most important being excessive oxidative stress and chronic low-grade inflammation superimposed on the limited cardiac regeneration capacity. Notably, a sizeable percentage of elderly HF patients have cardiac amyloidosis, an HF precipitator. This review summarizes the current published data on the mechanisms of cardiovascular aging as they contribute to the development of HF phenotype and outcome.